Loading the evidence…
Follow an intervention from preclinical studies to human trials and reported outcomes.
| THERAPY / MECHANISM | INJURY MODELS | STUDIES | REPORTED OUTCOME | Open record |
|---|---|---|---|---|
| (-)-Epigallocatechin-3-gallate Nutraceutical | Wound · Fracture +2 | 42013–2019 | Not approved | |
| 17beta-estradiol Estrogen receptor alpha agonist (AGONIST; direct interaction) | Spinal cord injury · Other +7 | 201999–2020 | No trauma translation | |
| 2-Octyl cyanoacrylate tissue adhesive Skin adhesive | Wound | 12020 | Not approved | |
| 6-hydroxydopamine chemical sympathectomy, timolol, isoepinephrine, tamsulosin, SB 225002, and neutralising anti-IL-6 and anti-IL-17A monoclonal antibodies Drug | Wound | 12019 | Not approved | |
| Acteoside from cistanche tea and its metabolites hydroxytyrosol, 3-hydroxyphenylpropionic acid and caffeic acid Nutraceutical | Endotoxin/LPS · Wound +1 | 32010–2019 | Not approved | |
| Adenosine triphosphate (ATP) Drug | Chemical/toxin · Wound | 22017–2020 | Not approved | |
| Atorvastatin HMG-CoA reductase inhibitor | Spinal cord injury · Other +3 | 62005–2018 | No trauma translation | |
| Boron derivatives: boric acid and sodium pentaborate pentahydrate, formulated as a hydrogel ATC S02AA03; inorganic, natural product and therapeutic flags set; max_phase 3, no first_approval recorded. get_mechanism was NOT called within the time budget, so moa_list is empty by OMISSION not by negative result. Sodium pentaborate pentahydrate was NOT separately searched and the hydrogel formulation has no ChEMBL entity, so this is a PARTIAL identity for boric acid only. All recorded trials are topical antimicrobial use in otomycosis, vulvovaginal candidiasis or eczema; NONE is a wound-healing or trauma indication. | Wound | 12016 | Not approved | |
| Calcipotriol, a synthetic vitamin D3 analogue Vitamin D receptor agonist | Wound | 12020 | No trauma translation | |
| Calcitriol (1,25-dihydroxyvitamin D3) Active vitamin D3; vitamin D receptor agonist. | Spinal cord injury · Wound +2 | 42015–2020 | No trauma translation | |
| Carbon monoxide-saturated saline (prepared by bubbling 50% carbon monoxide gas into saline) Drug | Chemical/toxin · Wound | 22016–2020 | Not approved | |
| Celecoxib Cyclooxygenase-2 inhibitor (INHIBITOR; direct interaction) | Wound · Chemical/toxin +1 | 11999–2018 | No trauma translation | |
| Chloramine T and chlorhexidine Cell membrane inhibitor (INHIBITOR); disrupts the bacterial cell membrane | Wound | 11986 | No trauma translation | |
| Colchicine Tubulin INHIBITOR; inhibits microtubule assembly by binding to beta tubulin (target CHEMBL2095182). ATC M04AC01. | Wound | 12017 | No trauma translation | |
| Collagenase Santyl Ointment (clostridial collagenase), active ingredient CS-API Collagen hydrolytic enzyme (HYDROLYTIC ENZYME) | Wound | 12018 | No trauma translation | |
| Copaiba oil-resin (Copaifera reticulata Ducke), 37.3% beta-caryophyllene beta-Caryophyllene (major sesquiterpene of copaiba oil-resin; reported CB2 receptor agonist); no curated ChEMBL mechanism record | Wound | 12017 | Not approved | |
| Cromolyn sodium Unknown | Wound · TBI +2 | 42010–2020 | No trauma translation | |
| Curcumin Nutraceutical | Spinal cord injury · Ischaemia-reperfusion +7 | 262002–2020 | Not approved | |
| Diclofenac Cyclooxygenase inhibitor (action type INHIBITOR; direct interaction, disease efficacy) | Chemical/toxin · Other +2 | 41983–2017 | No trauma translation | |
| Dimethyl sulfoxide Mechanism of action recorded in ChEMBL as 'Unknown'; approved intravesically for interstitial cystitis. | Wound · Other +2 | 41986–2018 | No trauma translation | |
| Dimethylfumarate and carnosol (Nrf2 activators) Alkylates Keap1 to prevent interaction with Nrf2 (INHIBITOR, direct interaction, disease efficacy true) | Chemical/toxin · Wound +1 | 32014–2018 | No trauma translation | |
| Doxycycline Bacterial 70S ribosome inhibitor (16S rRNA binding site); also inhibits matrix metalloproteinases MMP-1, MMP-7, MMP-8 and MMP-13, which ChEMBL notes is the primary action at concentrations reached in the human body | Other · TBI +3 | 72011–2020 | No trauma translation | |
| Epidermal growth factor Biologic | Chemical/toxin · Spinal cord injury +3 | 51989–2017 | Not approved | |
| Exherin (ADH-1), an N-cadherin-blocking synthetic peptide; plus AAV6-Cre and AAV6-CRISPR/Cas9 guide RNA for local N-cadherin (Cdh2) ablation N-cadherin (CDH2) antagonist; cyclic pentapeptide vascular-targeting agent (ChEMBL has no explicit mechanism record). Combination also includes AAV6-Cre and CRISPR/Cas9 for Cdh2 ablation. | Wound | 12020 | Not approved | |
| FG-4592 (roxadustat) HIF prolyl-hydroxylase (PHD) inhibitor; stimulates erythropoiesis. | Wound | 12018 | No trauma translation | |
| Fibroblast growth factor-2 (FGF2) encapsulated in poly(lactide-co-glycolide) nanoparticles embedded in a hyaluronan and methylcellulose (HAMC) hydrogel Fibroblast growth factor receptor 2 agonist | Wound · Spinal cord injury +1 | 42012–2015 | No trauma translation | |
| FK-506 (tacrolimus) FK506-binding protein 1A (FKBP1A) inhibitor; calcineurin/immunophilin immunosuppressive pathway | Spinal cord injury · TBI +2 | 72011–2017 | No trauma translation | |
| Granulocyte colony-stimulating factor (G-CSF) Granulocyte colony stimulating factor receptor agonist (AGONIST; direct interaction) | Spinal cord injury · Radiation +6 | 152006–2019 | No trauma translation | |
| Hepatocyte growth factor Drug | Wound · Ischaemia-reperfusion +2 | 111993–2009 | Not approved | |
| HOE 140 (icatibant) Bradykinin B2 receptor antagonist (ANTAGONIST) | Wound · Spinal cord injury | 22014–2019 | No trauma translation | |
| Human plasma-based fibrin matrix used as the culture support for epidermal substitutes No ChEMBL mechanism record. Match is to the fibrin biomaterial itself, not to the cultured epidermal-substitute construct. | Wound | 12019 | Not approved | |
| Human plasminogen Fibrinogen hydrolytic enzyme | Wound · Burn | 22012–2014 | Not approved | |
| Hyaluronan of differing molecular weights and concentrations, best outcomes with high molecular weight (3000 kDa) hyaluronan No mechanism record retrieved; ChEMBL molecule_type Unknown. ATC M09AX01, S01KA01, D03AX05, R01AX09. | Crush · Other +1 | 32016–2019 | No trauma translation | |
| Ibuprofen Cyclooxygenase inhibitor (INHIBITOR, direct interaction, disease efficacy true) | TBI · Wound +1 | 51985–2018 | No trauma translation | |
| Insulin Insulin receptor agonist (AGONIST; direct interaction) | Burn · Wound +3 | 81981–2019 | No trauma translation | |
| Interleukin-1 receptor antagonist (IL-1ra) Interleukin-1 receptor antagonist (ANTAGONIST; direct interaction) | Fracture · TBI +5 | 102010–2020 | No trauma translation | |
| L-arginine Drug | Chemical/toxin · Spinal cord injury +2 | 52011–2017 | Not approved | |
| L-NAME Drug | Ischaemia-reperfusion · Spinal cord injury +4 | 31997–2017 | Not approved | |
| L-tryptophan L-tryptophan (essential amino acid; serotonin precursor); no curated ChEMBL mechanism record | Wound | 12015 | Failed | |
| Lidocaine BLOCKER of the voltage-gated sodium channel alpha subunit (local anaesthetic; also class Ib antiarrhythmic). | Other · Wound +3 | 41990–2020 | No trauma translation | |
| Lipo-prostaglandin E1 (lipo-PGE1, alprostadil in lipid microsphere formulation) Prostanoid EP1 receptor agonist; Prostanoid EP2 receptor agonist (AGONIST) | Wound · Other | 22012–2015 | No trauma translation | |
| MCC950 Drug | Wound · Burn | 22016–2018 | Not approved | |
| Melatonin Melatonin receptor agonist (AGONIST); active at MT1, MT2 and MT3 receptors, MT1/MT2 most relevant; sleep promoting activity. | Chemical/toxin · Other +8 | 242003–2020 | No trauma translation | |
| Mifepristone (glucocorticoid receptor antagonist) and spironolactone (mineralocorticoid receptor antagonist) Glucocorticoid receptor antagonist; Progesterone receptor antagonist (ANTAGONIST) | TBI · Burn +1 | 11995–2016 | No trauma translation | |
| Mitomycin C DNA inhibitor (action_type INHIBITOR; direct interaction, disease efficacy true) | Wound | 12015 | No trauma translation | |
| Morphine Mu opioid receptor agonist (AGONIST), direct interaction, disease efficacy true. | Spinal cord injury · Fracture +2 | 122012–2020 | No trauma translation | |
| Muramyl dipeptide No ChEMBL mechanism_of_action record. MDP is the minimal peptidoglycan adjuvant motif; ChEMBL max_phase 1. | Wound | 11982 | Not approved | |
| N(omega)-hydroxy-nor-L-arginine (nor-NOHA) arginase inhibitor, and Tie2-cre-mediated conditional deletion of Arg1 Drug | Wound | 12013 | Not approved | |
| Paroxetine Serotonin transporter (SERT) reuptake inhibitor (INHIBITOR) | Wound | 12014 | No trauma translation | |
| Photodynamic therapy using methyl 5-aminolevulinate hydrochloride (MAL) followed by red light irradiation Prodrug converted intracellularly to protoporphyrin IX; on red-light irradiation generates singlet oxygen causing DNA damage and cell death. ChEMBL mechanism record 'DNA inhibitor', mechanism comment 'Photodynamic therapy'. Salt form CHEMBL1201093 (hydrochloride, Metvixia) is the dosed ingredient. ATC L01XD03. | Wound | 12020 | No trauma translation |
Study counts are reported at therapy level and can differ from the number of itemised publications. Outcomes are research classifications, not treatment recommendations.